In late April 2026, Viking Therapeutics reported a wider first‑quarter net loss of US$158.33 million as research and development spending accelerated, while confirming that its Phase 3 VANQUISH-1 and ...

Ligand said it was terminating the program as a result of its claim that Viking "materially breached its obligation to use Commercially Reasonable Efforts to develop and commercialize the TR-Beta ...

Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to ...

Ligand Pharmaceuticals has accused Viking Therapeutics of breaching obligations under their licensing deal for thyroid hormone receptor beta (TRβ) therapies and moved to terminate the program. Viking ...

Zante summarized profitability and liquidity, stating, "For the 3 months ended March 31, 2026, Viking recorded a net loss of $158.3 million or $1.37 per share" and "At March 31, 2026, Viking held cash ...

The stock could have plenty of room to run from current levels.